Health1 min read

STAT+: Most-favored nations policy makes drugmakers rethink launches abroad

By · Via STAT Health · Published by Everything Blog

In short

Pharmaceutical companies are actively reconsidering their international product rollouts due to the pressure imposed by most-favored nations policies. Concurrently, Eli Lilly has been hit with a lawsuit brought forward by a former sales representative. The plaintiff alleges she was terminated after voicing concerns that the company improperly promoted its diabetes medication, Mounjaro, for unapproved weight loss use.

Key points

  • Pricing rules tied to most-favored nations policies are directly disrupting international…: Pricing rules tied to most-favored nations policies are directly disrupting international drug launch plans.
  • Eli Lilly faces legal repercussions regarding allegations of unapproved off-label drug ma…: Eli Lilly faces legal repercussions regarding allegations of unapproved off-label drug marketing for Mounjaro.
  • Raising internal compliance concerns over marketing practices allegedly led to the termin…: Raising internal compliance concerns over marketing practices allegedly led to the termination of a sales representative.

Sources checked by our analysis pipeline: 1

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. Thanksgiving is approaching and I’ve yet to make an all-butter pie crust that doesn’t shrink. Any tips or suggestions appreciated!

Ex-employee says Lilly promoted GLP-1 drug off-label

A former Eli Lilly sales rep filed a lawsuit alleging that she was fired after complaining that the company promoted its Mounjaro diabetes drug as a weight loss treatment before receiving regulatory approval to do so.

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Health